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Abstract
Thrombin is one of the most extensively studied of all proteases. Its central role in the coagulation cascade as well as several
other areas has been thoroughly documented. Despite this, its consensus cleavage site has never been determined in detail.
Here we have determined its extended substrate recognition profile using phage-display technology. The consensus
recognition sequence was identified as, P2-Pro, P1-Arg, P19-Ser/Ala/Gly/Thr, P29-not acidic and P39-Arg. Our analysis also
identifies an important role for a P39-arginine in thrombin substrates lacking a P2-proline. In order to study kinetics of this
cooperative or additive effect we developed a system for insertion of various pre-selected cleavable sequences in a linker
region between two thioredoxin molecules. Using this system we show that mutations of P2-Pro and P39-Arg lead to an
approximate 20-fold and 14-fold reduction, respectively in the rate of cleavage. Mutating both Pro and Arg results in a drop
in cleavage of 200–400 times, which highlights the importance of these two positions for maximal substrate cleavage.
Interestingly, no natural substrates display the obtained consensus sequence but represent sequences that show only 1–
30% of the optimal cleavage rate for thrombin. This clearly indicates that maximal cleavage, excluding the help of exosite
interactions, is not always desired, which may instead cause problems with dysregulated coagulation. It is likely exosite
cooperativity has a central role in determining the specificity and rate of cleavage of many of these in vivo substrates. Major
effects on cleavage efficiency were also observed for residues as far away as 4 amino acids from the cleavage site. Insertion
of an aspartic acid in position P4 resulted in a drop in cleavage by a factor of almost 20 times.
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Introduction
Proteases are essential for a large number of important
biological processes such as fertilization, blood clotting, food
digestion and immunity, where they constitute approximately 2%
of the total human proteome [1]. A key to the regulation of these
processes is their ability to select the correct targets among a
myriad of substrates. This is made possible by the specific
recognition of substrate sequences containing typically 7–8
contiguous amino acid (aa) residues [2]. Some proteases are
highly specific, having relatively strict preferences for the majority
of these 7–8 aa and therefore only cleave a few selected targets,
whereas others cleave almost any substrate with the preferred aa in
the P1 position, i.e. adjacent to where the peptide bond is cleaved.
Experimental identification of the recognition sequences adds very
important information about a protease’s biological function,
facilitates the identification of proteases for site-specific proteolysis,
provides a basis for the design of good substrates for kinetic studies
and helps in the design of efficient inhibitors. There is also
considerable medical interest in proteases, with an estimated 14%
of all human proteases being investigated as potential targets in
drug development [3].
Thrombin is arguably the most extensively studied of all human
proteases. It is a serine protease with essential functions in blood
coagulation and in numerous other regulatory processes. Known
natural substrates for thrombin include coagulation factors V,
VIII, XI and XIII, protein C and fibrinogen [4]. It also activates
platelets via cleavage of protease-activated receptors (PAR) -1, -3
and -4. Interestingly, thrombin regulates the coagulation process
both positively, by cleaving prothrombin, FV and FVIII and
negatively, by cleaving protein C (reviewed in [4,5,6]). Due to its
vital importance, the substrate recognition profile of thrombin has
beenstudiedindetailsincetheearly1980s[7,8].Varioustechniques
have been used, including chromogenic peptide substrates and
combinatorial methods using libraries of substrate peptides with
fluorogenic leaving groups or fluorescence-quenched substrates (see
Table 1) [9,10]. These studies have shown a strong preference for
arginine in position P1 and for proline in position P2
[7,8,11,12,13,14]. Aliphatic aa have been seen to be preferred in
position P4 [14,15]. Position P19 almost always has serine,
threonine, glycine or alanine [14,16,17]. Aromatic aa are favored
in position P29 [18,19], and basic residues in position P39
[18,19,20]. Acidic residues are avoided, especially in positions P3
andP39[13,14,17].Thesestudies,whicharesummarizedinTable1
have resulted in a relatively detailed picture of the cleavage
specificity of thrombin. However, there are limitations with these
studies. The preferences for aa N terminally or C terminally of the
cleavage site have been determined separately. In other studies, one
or several positions have been fixed or only a limited number of
combinations have been tested. Interactions depending on subsite
cooperativity are subsequently and easily overlooked. To overcome
these problems we have now determined the extended cleavage
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31756T
a
b
l
e
1
.
C
o
m
p
a
r
i
s
o
n
o
f
s
e
l
e
c
t
e
d
s
t
u
d
i
e
s
s
i
n
c
e
1
9
8
1
e
s
t
a
b
l
i
s
h
i
n
g
t
h
e
s
u
b
s
t
r
a
t
e
r
e
c
o
g
n
i
t
i
o
n
s
e
q
u
e
n
c
e
o
f
t
h
r
o
m
b
i
n
.
S
t
u
d
y
(
R
e
f
e
r
e
n
c
e
)
M
e
t
h
o
d
P
4
P
3
P
2
P
1
P
1
9
P
2
9
P
3
9
P
4
9
R
e
m
a
r
k
s
P
o
z
s
g
a
y
1
9
8
1
(
7
)
3
5
p
N
A
c
h
r
o
m
o
g
e
n
i
c
s
u
b
s
t
r
a
t
e
s
n
.
d
.
B
u
l
k
y
D
-
a
a
P
(
R
)
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
S
u
b
s
i
t
e
c
o
o
p
e
r
a
-
t
i
v
i
t
y
L
o
t
t
e
n
b
e
r
g
1
9
8
3
(
8
)
2
4
p
N
A
c
h
r
o
m
o
g
e
n
i
c
s
u
b
s
t
r
a
t
e
s
n
.
d
.
H
y
d
r
o
P
h
o
-
b
i
c
P
R
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
C
h
a
n
g
1
9
8
5
(
1
2
)
P
o
l
y
p
e
p
t
i
d
e
h
o
r
m
o
n
e
s
a
n
d
d
e
r
i
v
a
t
i
v
e
s
H
y
d
r
o
p
h
o
b
i
c
H
y
d
r
o
p
h
o
b
i
c
P
G
R
R
N
o
t
D
E
G
N
o
t
D
E
-
-
N
a
t
u
r
a
l
p
e
p
t
i
d
e
s
s
e
l
e
c
t
e
d
b
y
h
o
m
o
l
o
g
y
C
h
a
n
g
1
9
8
5
(
3
6
)
D
i
g
e
s
t
i
o
n
o
f
m
o
u
s
e
k
a
p
p
a
l
i
g
h
t
c
h
a
i
n
s
-
-
P
V
R
K
T
S
-
-
-
t
o
c
h
r
o
m
o
-
g
e
n
i
c
s
u
b
s
t
r
a
t
e
s
K
a
w
a
b
a
t
a
1
9
8
8
(
1
1
)
B
o
c
-
X
Z
R
-
N
H
-
M
e
d
(
X
:
1
2
,
Z
:
1
5
)
n
.
d
.
D
(
O
-
B
z
l
)
P
(
R
)
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
N
o
t
a
l
l
a
a
r
e
p
r
e
s
e
n
t
e
d
L
e
B
o
n
n
i
e
c
1
9
9
1
(
1
3
)
1
)
1
7
p
N
A
c
h
r
o
m
o
g
e
n
i
c
s
u
b
s
t
r
a
t
e
s
n
.
d
.
(
n
.
d
.
)
P
/
A
/
G
V
R
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
2
)
M
u
t
a
g
e
n
e
s
i
s
o
f
p
e
p
t
i
d
e
s
c
o
r
r
e
s
p
o
n
d
i
n
g
t
o
p
r
o
t
e
i
n
C
P
7
-
P
5
9
(
V
)
N
o
t
D
(
P
)
(
R
)
(
L
)
(
I
)
N
o
t
D
(
G
)
S
u
b
s
i
t
e
c
o
o
p
e
r
a
-
t
i
v
i
t
y
E
b
e
r
t
1
9
9
1
(
2
0
)
M
u
t
a
g
e
n
e
s
i
s
o
f
R
t
o
S
o
r
N
i
n
f
i
b
r
i
n
o
g
e
n
A
a
(
G
)
(
G
)
(
V
)
(
R
)
(
G
)
(
P
)
R
(
V
)
O
n
l
y
R
,
S
o
r
N
i
n
P
3
9
T
h
e
u
n
i
s
s
e
n
1
9
9
3
(
1
7
)
M
u
t
a
g
e
n
e
s
i
s
o
f
a
n
t
i
t
h
r
o
m
b
i
n
-
I
I
I
(
p
s
e
u
d
o
s
u
b
s
t
r
a
t
e
)
(
I
)
(
A
)
N
o
t
D
(
G
)
(
R
)
S
A
/
G
/
T
(
L
/
V
)
(
N
)
N
o
t
E
(
P
)
S
u
b
s
i
t
e
c
o
o
p
e
r
a
-
t
i
v
i
t
y
L
e
B
o
n
n
i
e
c
1
9
9
6
(
1
8
)
2
1
f
l
u
o
r
e
s
c
e
n
c
e
-
q
u
e
n
c
h
e
d
s
u
b
s
t
r
a
t
e
s
(
A
b
z
-
V
G
P
R
S
X
X
L
K
(
D
n
p
)
D
)
(
V
)
(
G
)
(
P
)
(
R
)
(
S
)
F
/
W
/
A
n
o
t
D
/
E
K
/
W
/
Q
N
o
t
D
(
L
)
R
n
o
t
a
m
o
n
g
1
0
r
e
p
r
e
-
s
e
n
t
e
d
a
a
V
i
n
d
i
g
n
i
1
9
9
7
(
3
7
)
8
p
N
A
c
h
r
o
m
o
g
e
n
i
c
s
u
b
s
t
r
a
t
e
s
(
P
1
:
R
/
K
;
P
2
:
P
/
G
;
P
3
:
V
/
F
)
n
.
d
.
V
P
R
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
S
u
b
s
i
t
e
c
o
o
p
e
r
a
-
t
i
v
i
t
y
M
a
r
q
u
e
2
0
0
0
(
1
9
)
3
8
f
l
u
o
r
e
s
c
e
n
c
e
-
q
u
e
n
c
h
e
d
s
u
b
s
t
r
a
t
e
s
(
A
b
z
-
V
G
P
R
S
X
X
L
K
(
D
n
p
)
D
)
(
V
)
(
G
)
(
P
)
(
R
)
(
S
)
F
/
Y
/
W
/
R
R
/
K
(
L
)
X
i
s
n
o
t
C
B
a
c
k
e
s
2
0
0
0
(
1
5
)
F
l
u
o
r
o
g
e
n
i
c
s
u
b
s
t
r
a
t
e
l
i
b
r
a
r
y
,
6
8
5
9
m
e
m
b
e
r
s
(
A
c
-
X
X
X
K
-
A
M
C
)
N
I
l
e
/
L
I
F
X
P
(
K
)
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
P
1
:
K
P
e
t
r
a
s
s
i
2
0
0
5
(
1
4
)
1
)
F
l
u
o
r
o
g
e
n
i
c
p
o
s
i
t
i
o
n
a
l
s
c
a
n
n
i
n
g
;
6
w
e
l
l
s
a
`
3
6
1
s
u
b
s
t
r
a
t
e
s
N
I
l
e
/
L
Q
/
S
/
T
/
R
P
R
n
.
d
.
n
.
d
.
n
.
d
.
n
.
d
.
X
i
s
n
o
t
C
P
e
t
r
a
s
s
i
2
0
0
5
(
1
4
)
2
)
B
i
a
s
e
d
d
o
n
o
r
-
q
u
e
n
c
h
e
r
l
i
b
r
a
r
y
;
1
9
s
u
b
l
i
b
r
a
r
i
e
s
a
`
6
8
5
9
m
e
m
b
e
r
s
(
L
T
P
R
X
X
X
X
)
(
L
)
(
T
)
(
P
)
(
R
)
S
/
A
T
/
G
N
o
t
D
E
N
o
t
D
E
X
N
o
s
p
e
c
i
f
i
c
P
3
9
a
n
d
P
4
9
p
r
e
f
e
r
e
n
c
e
f
o
u
n
d
T
h
i
s
s
t
u
d
y
P
h
a
g
e
-
d
i
s
p
l
a
y
e
d
9
-
m
e
r
l
i
b
r
a
r
y
,
,
5
6
1
0
7
m
e
m
b
e
r
s
L
/ G G
/
T
/
R
/
M
V
P
/
G
/
V
R
S
A
G
/
T
W
/
G
/
F
S
R
V
/
L
S
R
S
u
b
s
i
t
e
c
o
o
p
e
r
a
-
t
i
v
i
t
y
L
e
t
t
e
r
s
i
n
b
o
l
d
i
n
d
i
c
a
t
e
s
i
n
v
e
s
t
i
g
a
t
e
d
p
o
s
i
t
i
o
n
s
,
r
e
s
i
d
u
e
s
t
h
a
t
w
e
r
e
h
e
l
d
c
o
n
s
t
a
n
t
a
r
e
i
n
p
a
r
e
n
t
h
e
s
e
s
.
T
h
e
p
r
e
f
e
r
r
e
d
a
m
i
n
o
a
c
i
d
s
a
r
e
d
e
n
o
t
e
d
i
n
t
h
e
o
r
d
e
r
o
f
p
r
e
f
e
r
e
n
c
e
.
E
q
u
a
l
l
y
f
a
v
o
r
a
b
l
e
r
e
s
i
d
u
e
s
a
r
e
i
n
d
i
c
a
t
e
d
b
y
t
h
e
a
b
s
e
n
c
e
o
f
a
s
l
a
s
h
(
/
)
.
n
.
d
.
,
n
o
t
d
e
t
e
r
m
i
n
e
d
;
-
,
n
o
t
a
p
p
l
i
c
a
b
l
e
;
p
N
A
,
p
a
r
a
-
n
i
t
r
o
a
n
i
l
i
d
e
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
1
7
5
6
.
t
0
0
1
The Extended Cleavage Specificity of Thrombin
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31756specificity of thrombin using phage substrate display technology.
This method utilizes a library of approximately 5610
7 bacterio-
phages [21] where one capsid protein displays a randomized,
individual oligopeptide sequence coupled to a six histidine
purification tag. Protease-susceptible oligopeptide sequences are
identified and amplified, usually in five rounds of selection, so that
all final sequences have been selected by the protease of interest
during five different occasions. The competition of suitable targets
at a low concentration with countless non-substrate molecules for
access to the active site probably closely resembles in vivo situations.
Phage display allows the simultaneous investigation of primed
and non-primed substrate positions, and can inform about subsite
cooperativity. Compared to the analysis of individual peptides,
which is also sensitive to subsite cooperativity, phage display has
the advantage that numerous sequences can be investigated in a
short time. Other advantages include that phage display is virtually
unbiased, works independently of the P1 specificity and tolerates
big variations in the degree of selectivity. It is only when proteases
requiring a three-dimensional substrate structure that is not
provided by phage-displayed peptides the method may fail [22].
Phage display has already been successfully applied to proteases
preferring various aa in the P1 position including aspartate
(Granzyme B), glutamate (ADAMTS-4), arginine (OmpT, kalli-
krein-2), phenylalanine (rMCP-4, mMCP-1, mMCP-4, human
chymase, dog chymase), tryptophan (opossum chymase) alanine or
asparagine (MMP-11), or valine/alanine/isoleucine (rMCP-5)
[21,23,24,25,26,27,28,29,30,31,32,33]. Consensus motifs identi-
fied from such analyses are present in physiological substrates and
can be used in the search for novel targets. Peptides corresponding
to the consensus motifs and mutations of these sequences can also
be used for kinetic analyses.
In this communication we present a detailed analysis of the
extended cleavage specificity of the active site of human thrombin,
minimizing the influence on cleavage specificity by long-distance
exosite interactions. This analysis conforms very well to the
previously observed preferences, as summarized in Table 1. In
addition, the phage display results suggest a cooperative or
additive effect between subsites P2 and P39. A comparison
between the consensus sequence and a panel of known in vivo
substrates also showed that no natural substrates display the
consensus sequence but represent sequences that show only 1–
30% of the optimal cleavage efficiency for thrombin. This very
interesting finding indicates that maximal cleavage, in the absence
of exosite interactions, is not always desired but instead may cause
problems with excessive or dysregulated coagulation. A low
cleavage rate of the selected sequence may be strongly enhanced
by strong and specific exosite interactions.
Moreover, we present a screening of the human proteome for
potential novel thrombin targets using the derived consensus
cleavage motif, Pro-Arg-[AlaGlySerThr]-[not AspGlu]-Arg (i.e. P-
R-[AGST]-[not DE]-R). A list of 73 such potential targets is
presented where the majority are involved in cell adhesion, the
nervous system, development/differentiation and circulatory
homeostasis. Some of them may prove to be novel important
targets for this multifaceted enzyme.
Results
Phage display analysis of the extended cleavage
specificity of human thrombin
A library of T7 phage-displayed nanomer peptides was
subjected to five rounds of selection with 0.2 U or 1 U of human
thrombin (1.5 and 7.5 nM of thrombin) [21,33,34]. This library
contains approximately 5610
7 independent bacteriophages [21].
The ratio of phages released in thrombin-treated samples
compared to the PBS control increased steadily with each
selection round, reaching 240 in samples with 1 U thrombin
and 136 with 0.2 U of thrombin after five selection rounds (data
not shown). Seventeen or eighteen DNA sequences coding for
cleavage-susceptible peptides were sampled from plaques repre-
senting selection with 0.2 U or 1 U of thrombin, respectively. All
sequences were aligned to the most frequently observed pattern of
at least four aa, i.e. [other]-[basic]-[small hydrophobic]-X-[basic]
(Fig. 1A, 1F). The consensus could then be refined to P-R-
[AGST]-[not DE]-R. This consensus closely reflects the collected
results from thirteen previous studies (Table 1). The strongest
preference was observed for the first arginine in the consensus,
which is therefore likely to represent the P1 position as determined
from the phage display results. This is in accordance with
previously established data (see Table 1).
Notably, we retrieved seven inserts from thrombin-selected
phages where the sequence flanking the random nonapeptide
amino-termini was mutated to encode Leu-Thr-Pro-Arg-Gly
instead of Leu-Thr-Pro-Gly-Gly (‘‘!’’ in Fig. 1). Five of these
sequences have arginine in position P39, in accord with the refined
consensus. We have never before observed mutations in the non-
randomized region of selected peptides [21,28,33]. The retrieval of
these sequences in the present study demonstrates that even very
infrequent sequences that represent good substrates can be
recovered by phage display.
Amino acid prevalence in positions P4 to P49 as derived
by phage display conforms with natural substrates and
previous studies
Based on our alignments, we analyzed the prevalence of aa in
each single position (Fig. 2) and, as stated above, thrombin’s long-
known requirement for arginine in position P1 was reproduced
[8,9,12,35]. In position P2, the well-established proline
[7,8,11,12,36,37] dominated (71%), but also aliphatic aa were
tolerated. P2 glycine, valine or isoleucine were together present in
23% of the sequences. Although several earlier studies report
similar findings, recent studies have mostly focused on P2 proline
(see Table 1). However, aliphatic P2 residues are present in a
number of natural thrombin substrates (Fig. 1C), including
fibrinogen Aa and Bb, two cleavage sites in factor V (R737 and
R1573), and PAR-3.
Position P3 was not very restricted, but excluded negatively
charged aa. The most frequent residues here were glycine (29%),
threonine (23%) and arginine (17%) (Fig. 2), three aa with differing
biochemical and structural characteristics. A broad specificity as
well as an exclusion of acidic residues, has previously been
observed for position P3 [8,13,14,15]. Intriguingly, several natural
substrates have acidic P3 residues, e.g. factor VIII (site R759),
PAR-1 (site R41), rat fibrinogen a/a-E and protein C. The
negative contribution of the acidic residue may here be
compensated for by exosite interactions. In line with this view, a
synthetic peptide corresponding to protein C residues P7 to P59 is
in itself a poor thrombin substrate [13].
A more restricted preference was found in position P4, with
aliphatic glycine or leucine in 31% or 37% of the sequences,
respectively. This is in accordance with previous reports [14,15].
Furthermore aliphatic P4 residues are frequently found in natural
substrates (Fig. 1 and [12]).
On the primed side, in position P19, we found only glycine
(29%), alanine (29%), serine (29%) or threonine (14%). Studies
using mutagenesis analysis [17] or a fluorescence-quenched library
[14] have reported the same four preferred P19 residues (see
Table 1). These P19 aa are also very common among natural
The Extended Cleavage Specificity of Thrombin
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[12,36,38]).
Position P29 displayed rather broad specificity, with aromatic
residues (phenylalanine, tyrosine, tryptophan) in 34%, and
aliphatic residues (glycine, alanine, valine, leucine) in 37% of the
sequences. Aromatic and aliphatic P29 aa are frequent in natural
substrates (Fig. 1 and [12,36]). Preference for aromatic P29
residues has also been reported from studies with fluorescence-
quenched substrates [18,19].
In position P39, we observed a strong preference for arginine
(69%), similar to results obtained with fluorescence-quenched
substrates [18,19]. The possibility of subsite cooperative effects
involving position P39 are discussed below.
Position P49 was quite unspecific. The five most frequent aa
were valine (20%), leucine (14%), serine (14%), arginine (14%) and
histidine (9%). Aliphatic residues are frequent in the P49 position
of natural substrates, but P49 is probably not a major specificity
determinant. One previous study including the P49 position also
found a broad tolerance of aa [14].
Phage display results indicates an arginine in position P39
is important in substrates lacking proline in position P2
After aligning the phage-displayed peptides, we analyzed the
representation of the consensus within the single sequences.
Interestingly, we observed that all thrombin-susceptible peptides
with residues other than proline in position P2 hold arginine/
lysine in position P39, whereas this is the case in only 64% of the
peptides with a P2 proline (Fig. 1). This indicates that binding of
substrate residues P2 and P39 to their thrombin subsites may be
partially interdependent (subsite cooperativity).
Natural substrates where P2 is not proline, such as fibrinogen
Aa and Bb, factor V (site R737), PAR-1 (site R25) and PAR-3
hold arginine in position P39, whereas most substrates with proline
in position P2 do not hold arginine in the P39 position (Fig. 1C).
The phage display results indicate that P2 proline and P39 arginine
are not mutually exclusive. Rather, the absence of an advanta-
geous P2 residue, proline, in some substrates seems to be
compensated for by the presence of an advantageous P39 residue,
arginine.
Verifying the consensus sequence by the use of a new
type of recombinant substrate
In order to verify the results from the phage display analysis and
to estimate the importance of individual aa positions for the rate of
cleavage, a new type of recombinant substrate was developed. The
consensus sequence obtained from the phage display analysis was
inserted in a linker region between two E.coli thioredoxin
molecules. A number of mutations in individual aa positions from
this consensus sequence, the cleavage sites of a few in vivo
substrates, and a few unrelated substrate sequences were also
produced with this system. This was achieved by ligating the
corresponding oligonucleotides into the BamHI/SalI sites of the
vector (Fig. 3A and Table 2). All of these substrates were expressed
as soluble proteins and purified to obtain a protein with a purity of
Figure 1. Alignment of sequences obtained after five selection
rounds with 1 U of thrombin or 0.2 U of thrombin, compared
to natural substrates. Panel A shows the result with 1 U of thrombin,
panel B the result with 0.2 U of thrombin and panel C a panel of natural
substrates. The P1 residue in natural substrates (after which cleavage
occurs) is denoted in parentheses. Substrate sequences refer to Homo
sapiens where not indicated otherwise.! marks phage sequences that
have LTPRG instead of LTPGG in the N-terminal flank. Residues from the
non-randomized phage region are in italics. *, from Rattus norvegicus;
IGFBP, insulin-like growth factor-binding protein; PAR, protease-
activated receptor. The cleavage site of thrombin in the natural
substrates listed in panel C is numbered from the N terminal of the pre-
pro protein, from the first methionine. This list of natural substrates is a
selection of a few of the most well known substrates of this enzyme.
However, the list of potential in vivo substrates is much longer and
includes many other proteins such as protein S, TAFI, antithrombin,
heparin cofactor II and nexin I.
doi:10.1371/journal.pone.0031756.g001
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preference of human thrombin for the different sequences (Figs. 3
and 4). The same concentration (18 mM) of all substrates was used
in all experiments to obtain quantitative measurements of relative
cleavage rate between the different sequences. The same
concentration of thrombin (9 nM) was also used in all experiments
except in two instances. When studying the cleavage of a few poor
substrates for thrombin where we also determined the cleavage of
the same amount of substrate, three or ten times more of the
enzyme was added (Fig. 3). In most experiments the ratio substrate
to protease was therefore approximately 2000.
Thrombin was found to very efficiently cleave the consensus
sequence (LTPRGVRL). By changing the proline residue in the
P2 position of the thrombin consensus sequence into a valine, the
second most preferred aa, based on the phage display result,
(LTVRGVRL)) the efficiency of cleavage by thrombin dropped by
a factor of approximately 20 (Fig. 3B and 3D). By changing the
arginine residue in the P3 position of the thrombin consensus
sequence into a leucine, also the second most preferred aa based
on the phage display result, (LTPRGVLL)) the efficiency of
cleavage by thrombin dropped by a factor of 10–15 (Fig. 3B and
3D). Altering both the proline residue in the P2 position and the
arginine in position P39of the thrombin consensus sequence into a
valine and leucine respectively, (LTVRGVLL)) the efficiency of
cleavage by thrombin dropped by a factor of 200–400 (Fig. 3B and
3D). These results show the major importance of these two
residues in conferring the substrate specificity of thrombin.
When analyzing the phage display results in detail, we also
observed that no aromatic aa are present in position P19. This
position was relatively unspecified with approximately equal
representation of four different aa glycine (29%), alanine (29%),
serine (29%) or threonine (14%). A tryptophan was inserted in the
P19position (LTPRWVRL) and tested for efficiency in cleavage.
No cleavage of this substrate was observed, indicating that no large
bulky aa is tolerated in this position. Similarly, in position P3 we
did not observe any aromatic aa and only one example of an
aromatic aa is found for this position in the natural substrates listed
in Figure 1 (Factor V (R1573)). A substrate was produced where
tryptophan was introduced in position P3 instead of the preferred
threonine (LWPRGVRL). However, this mutation had no effect
on the cleavage rate (Fig. 3C).
A lack of negatively charged aa in position P29and P39 has been
observed. Therefore a mutant where an aspartic acid was inserted
in position P29 was tested (LTPRGDRL). This substrate showed a
reduction in cleavage by approximately 15 times compared to
consensus. The effect of this mutation was almost as severe as
mutating the proline in position P2 and as severe as mutating
arginine in the P39position. In contrast, introducing an aspartic
acid in position P49 (LTPRGVRD) had only a minor effect on the
rate of cleavage, by a factor 2–3, compared to the consensus
(Fig. 3C).
A number of additional substrates were also included in this
study. The optimal sequence for cleavage by the human mast cell
chymase (HC) and the opossum mast cell chymase (OC) have
recently been determined [29,31]. When analyzing the cleavage of
these two sequences (VGLWLDRV and VVLFSEVL) we
observed that human thrombin leaves these sequences completely
Figure 2. Amino acid frequency in positions P4 to P49 of
thrombin-susceptible phage sequences. This analysis is based on
the alignments shown in Figure 1A and 1B. For clarity, amino acids are
displayed in functional groups, starting to the left with aromatic
residues, and ending with acidic residues to the right.
doi:10.1371/journal.pone.0031756.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31756Figure 3. Analysis of the cleavage specificity by the use of new types of recombinant protein substrate. Panel A shows the overall
structure of the recombinant protein substrates used for analysis of the efficiency in cleavage by thrombin. In these substrates two thioredoxin
molecules are positioned in tandem and the proteins have a His6-tag positioned in their C termini. The different cleavable sequences are inserted in
the linker region between the two thioredoxin molecules by the use of two unique restriction sites, one Bam HI and one SalI site, which are indicated
in the bottom of panel A. Panels B to E shows the cleavage of a number of substrates by thrombin, where individual amino acids has been changed
from the thrombin consensus sequence. The name and sequence of the different substrates are indicated above the pictures of the gels. The time of
cleavage (in minutes) is also indicated above the corresponding lanes of the different gels. The uncleaved substrates have a molecular weight of
approximately 25 kDa and the cleaved substrates appear as two closely located bands with a size of 12–13 kDa.
doi:10.1371/journal.pone.0031756.g003
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result shows the high selectivity in substrate selection by thrombin.
Following the initial screening we felt that these results were so
interesting that we decided to extend the analysis to a number of
additional substrates. From the phage display data we had
observed an almost complete lack of negatively charged aa in all
eight aa positions surrounding the cleavage site. Therefore an
aspartic acid residue was placed in various positions in the
substrate. The insertion of an aspartic acid in the P4 position
(DTPRGVRL) showed surprisingly a major effect on cleavage, a
drop in efficacy by a factor 20–30 (Fig. 4A). Interestingly, insertion
of an aspartic acid in position P3 (LDPRGVRL) had a much less
pronounced effect. Here efficacy dropped by a factor 2–3 (Fig. 4A).
However, the insertions of an aspartic acid in positions P2 or P19
had dramatic effects (LTDRGVRL and LTPRDVRL)). An
almost complete lack of cleavage was observed (Fig. 4A and 4B).
Insertion of an aspartic acid in the P39position also showed a
marked effect on cleavage, by a factor of approximately 20–30
times that of the consensus sequence (Fig. 4B).
None of the substrates obtained from the phage display analysis
had lysine in the P1 position. However one in vivo substrate, PAR-
3, has been shown to have a lysine in this position (Fig. 1C). In
order to test the selectivity for arginine over lysine (both positively
charged aa) we exchanged arginine for lysine in one of the
synthetic substrates (LTPKGVRL) (Fig. 4B). Interestingly the
analysis of the cleavage rate of this substrate showed that arginine
is preferred over lysine by a factor of approximately 10 (Fig. 4B),
indicating a relatively high selectivity for arginine in the P1
position.
From the previous analysis we had seen that introduction of an
aromatic aa in thee P19 position completely blocked cleavage,
therefore we decided to test other aa substitutions in this position.
Introducing an aspartic acid in this position also completely
blocked cleavage, whereas a leucine in this position (LTPRLVRL)
showed an approximate 10-fold reduction in cleavage (Fig. 4C).
Insertion of a tryptophan in position P29, instead of the
consensus valine, (LTPRGWRL) had no or even a minor positive
effect on the rate of cleavage.
When we compared the consensus sequence obtained from the
phage display analysis with the list of natural in vivo substrates
presented in Figure 1C, we observed that no in vivo substrate
corresponded to the consensus sequence. Interestingly, the natural
substrates appeared to be relatively poor substrates for human
thrombin. In order to substantiate this conclusion, we selected four
relatively different in vivo substrates and produced recombinant
substrates containing the eight aa region spanning these three
cleavage sites. The first substrate tested corresponded to arginine
211 in protein C (substrate number 16 in Figure 4C). This
sequence (VDPRLIDG) was found to be a very poor substrate for
thrombin. In our analysis we could not detect any cleavage after
150 minutes, which shows that it is 1% or below of the cleavage of
the consensus substrate. The second in vivo substrate that was
analyzed was the region of arginine 327 in prothrombin
(FNPRTFGS). This substrate showed relatively good cleavage
(Fig. 4D). However, only 25–30% cleavage compared to the
consensus substrate was observed (Fig. 4D). The third in vivo
substrate (substrate 18) was another cleavage site within pro-
thrombin. This site, which corresponds to the region around
arginine 200 (MTPRSEGS) was a poor site for thrombin
cleavage. This site was 20–30 times less efficient than the
consensus site (Fig. 4D). The fourth in vivo site that was studied
was the region corresponding to arginine 35 in fibrinogen A alpha
(GGVRGPRV). This site was also a very poor site for thrombin.
Similarly to the protein C substrate no cleavage could be detected
even after 150 minutes, again showing it is 1% or less than the
activity of the consensus site (Fig. 4D). All these four ‘‘in vivo’’
substrates were cleaved at less than 25–30% efficiency compared
to the consensus substrate (Fig. 4C and 4D). This confirmed our
conclusion based on the phage display analysis that most natural in
vivo substrates are relatively poor substrates for human thrombin
when presented as linear peptides. Long range exosite cooperative
effects here may help in increasing the local concentration of the
substrate and thereby increasing the rate of cleavage. The data
from the recombinant substrate analysis has been summarized in
Table 2.
Novel candidate substrates for thrombin identified by
PROSITE search
Known natural thrombin substrates mostly align to only three
or four positions in the consensus recognition sequence, P-R-
[AGST]-[not DE]-R. Thus, database searches with the full
consensus may identify novel potential thrombin substrates. We
searched the Swiss-Prot, TrEMBL and PDB databases for human
(H. sapiens) proteins holding the P-R-[AGST]-[not DE]-R motif,
yielding 651 hits in 602 protein sequences. In at least 75 proteins,
the motif was extra-cellular or secreted (Tables 3, 4, 5 and 6) and
therefore potentially accessible for thrombin. Interestingly, a total
73 of these proteins seem involved in one or several of four areas
including, cell adhesion, the nervous system, development and
differentiation or circulatory homeostasis (Tables 3, 4, 5, and 6).
More specifically, 36 proteins (48%) have been implicated in cell
adhesion. Among these are eight collagen variants and integrin
aV, i.e. central components of the extra-cellular matrix (ECM).
Thirty-three proteins (44%) have roles in the nervous system,
including three roundabout homologs and persephin, all of which
are implied in neurotropic activity. Thirty proteins (40%) are
involved in development/differentiation, and eleven (14.7%) in
circulatory homeostasis.
Discussion
Substrate phage display technology has made it possible to
elucidate the substrate recognition profile of human thrombin
from position P4 to P49, completely and simultaneously.
Table 2. Amino acid summary of thrombin cleavage
sequences.
Variant Cleavable sequence Variant Cleavable sequence
Consensus LTPRGVRL 100% 11 LTPRDVRL 0%
1L T VRGVRL 5% 12 LTPRGVDL 3–4%
2 LTPRGVLL 8% 13 LTPKGVRL 15%
3L T VRGVLL 0.3% 14 LTPRLVRL 15%
4L WPRGVRL 100% 15 LTPRGWRL 150%
5 LTPRWVRL 0% 16 VDPRLIDG 1–2%
6 LTPRGDRL 5% 17 FNPRTFGS 25%
7 LTPRGVRD 40% 18 MTPRSEGS 1–2%
8 DTPRGVRL 3–4% 19 GGVRGPRV 1%
9L DPRGVRL 5–10%
10 LTDRGVRL 0%
Amino acids shown in bold and larger font are deviations from the preferred
thrombin consensus sequence. The cleavage efficiency compared to the
consensus is shown as a percentage.
doi:10.1371/journal.pone.0031756.t002
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detail substantially but also conforms relatively well with results
presented in reports during the past 25 years (see Table 1). It
should also be pointed out that only two previous studies report
results for eight positions [14], but P1 to P4 and P19 to P49 were, in
one of these studies, investigated separately and with two different
approaches. Moreover, distinct subsites were held constant or not
investigated, which effectively prevents the analysis of subsite
cooperativity effects. The results for positions P29,P 3 9and P49
reported from that work were also less specific than with phage
display. The second study is a phage display analysis that was
performed on human thrombin and on thrombin in combination
with thrombomodulin or hirugen [39]. However, only a diagram
on residue preferences was included; there are no original data
about individual clones. Furthermore, the high variability in the
analysis made it difficult to draw any conclusions for a potential
consensus cleavage site [39].
When we compare our phage display data with previous
investigations the strong preferences for arginine in position P1
[8,9,12,35] and for proline in position P2 [7,8,11,12,36] was
Figure 4. Analysis of the cleavage specificity by the use of new types of recombinant protein substrate. Panels A to D shows the
cleavage of a number of substrates by thrombin, where individual amino acids has been changed from the thrombin consensus sequence. The name
and sequence of the different substrates are indicated above the pictures of the gels. The time of cleavage (in minutes) is also indicated above the
corresponding lanes of the different gels. Variants 16 is the Protein C cleavage site R211, variant 17 is the Prothrombin site R327, variant 18 is the
Prothrombin site R200 and variant 19 is the Fibrinogen A alpha site R35 (see Figure 1).
doi:10.1371/journal.pone.0031756.g004
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However, negatively charged aa have previously been reported not
to be tolerated in this position [13]. In contrast to this finding we
observe a remarkable high tolerance for most aa acids in this
position including negatively charged aa (Fig. 1 and Fig. 4).
Position P4 featured preferentially hydrophobic aa, namely
leucine, which has been the most frequent aa reported by several
studies as well as ours [14,15]. Here we can report a remarkably
high degree of specificity. Negatively charged aa are apparently
not tolerated in this position as we see a drop in cleavage by 20–30
times by introducing an aspartic acid in this position (Fig. 4). For
position P19, our study and two others [14,17] have consistently
identified serine, alanine, glycine and threonine to be by far the
most preferred residues. Aromatic aa were the most preferred in
position P29. Le Bonniec and Marque with coworkers have
reported phenylalanine to be most preferred [18,19] and we
indicate tryptophan is the most prevalent with phenylalanine as
the third most frequent aa. In position P39, our data along with
others, found arginine to be most preferred [19,20]. Position P49
has previously not been extensively investigated, but seems to
display a preference for aliphatic residues.
Substrates aligning to the consensus in positions P1, P19and P29
may obtain sufficient affinity to thrombin by either a proline in the
P2 position (which is well-documented), but also in the absence of
P2 proline by an arginine in position P39. However, the thrombin
consensus recognition sequence does not indicate this, because
most experimental thrombin substrates obtained by phage display
hold both proline in position P2 and arginine in P39. The
cooperativity effects involving position P39 have previously also
been indicated from mutagenesis studies of single peptides [13,17].
Table 3. Potential novel thrombin substrates.
ID/
Functional
grouping Name (Presumable) function Motif Positions
Location
in protein Protein expression
P11230
A B CD
Acetylcholin receptor subunit b Synaptic transmission PRGGR 224–228 24–244 ED
(multi-pass)
Neurons, muscle
Q6UY14
ABCD
ADAMTS-like protein 4 Stimulates apoptosis PRGIR 424–428 Secreted Lung, plasma,
placenta,
Q9UKB5
A BCD
Adherens junction-associated
protein 1
Cell adhesion and migration PRARR 96–100 1–282 ED Uterus, pancreas
O00253
A B CD
Agouti-related protein Weight homeostasis PRSSR 81–85 Secreted Brain, testis lung,
kidney
Q9BXJ7
ABCD
Amnionless protein Vit. B12 absorption, directs
trunk mesoderm
PRSSR 195–299 20–357 ED Kidney, testis,
thymus, PBL, colon,
small intestine
Q9Y5L1
A B C D
Angiopoietin-related protein 3 Cell-matrix adhesion, lipid
metabolism, angiogenesis
PRAPR 220–224 Secreted Liver (kidney)
Q6SPF0
ABC D
Atherin Atherogenesis by immobilizing
LDL in arterial wall
PRAPR 112–116 Cytoplasmic/
secreted
Atherosclero-tic
lesions
P01160
ABCD
Atrial natriuretic factor Cardiovascular homeostasis PRSLR 122–126 Secreted; 56–122
propeptide
O14514
ABCD
Brain-specific angiogenesis
inhibitor 1
Inhibits angiogenesis in brain;
cell adhesion, signal transduction
PRSLR 861–865 31–948 ED
(7-TM)
Brain
Q9NYQ6
ABC D
Cadherin EGF LAG seven-pass
G-type receptor 1
Cell-cell signalling during formation
of the nervous system, planar polarity
PRAPR 58–62 22–2469 ED
Q9NYQ7
ABC D
Cadherin EGF LAG seven-pass
G-type receptor 3
Cell-cell signalling during
formation of the nervous system
PRTAR
PRGAR
249–253
2337–2341
33–2540 ED
Q96IY4
ABC D
Carboxypeptidase B2 (Thrombin-
activable fibrinolysis inhibitor)
Cleaves kinins and
anaphylatoxins
PRTSR 33–37 Secreted; 23–114
activation peptide
Plasma; synthesized
in liver
Q16619
ABC D
Cardiotrophin-1 Induces cardiac myocyte
hypertrophy
PRAPR 113–117 Secreted Heart, ovary,
prostate, skeletal
muscle
Q9H2X0
ABCD
Chordin Key developmental dorsalizing
factor
PRGCR 869–873 Secreted Early vertebrate
tissues
P02452
ABC D
Collagen a1(I) chain Epidermis and skeletal
development
PRGPR 119–123 Secreted Brain, spleen, tendon,
ligaments, bones
P02461
A BCD
Collagen a1(III) chain
(Goodpasture antigen)
Homotrimers in most soft
connective tissues
PRGNR 1165–1169 Secreted Skin, placenta, liver
P20908
A BCD
Collagen a1(V) chain Binds DNA, heparan sulfate,
heparin, thrombospondin, insulin
PRGQR 908–912 Secreted Nearly ubiquitous
P12107
A BCD
Collagen a1(XI) chain Trimer a1(XI), a2(XI), a3(XI) may
control growth of collagen II fibrils
PRGQR
PRGSR
878–882
887–891
Secreted Cartilage, placenta
Hits holding the consensus P-R-[AGST]-[not DE]-R in an extra-cellular or secreted part are listed alphabetically by name. In the column to the left, A in bold and larger
font indicates (presumable) involvement in cell adhesion, B in the nervous system, C in the cardiovascular system, and D in development/differentiation. ED, extra-
cellular domain; 7-TM, seven-transmembrane receptor; PBL, peripheral blood leukocytes.
doi:10.1371/journal.pone.0031756.t003
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was held constant in these studies, and several cooperativity
mechanisms may exist.
Several important physiological thrombin targets do indeed lack
proline in position P2 and hold arginine in P39, e.g. fibrinogen
chains Aa and Bb, factor V, PAR-1 and PAR-3 (Fig. 1C).
However, the preferred and activating PAR-1 cleavage by
thrombin is LDPR-SFLL holding P2 proline. The P39 arginine
in fibrinogen Aa has great biologic significance, as illustrated by
the fact that replacement of this residue with glycine, serine or
asparagine leads to bleeding disorders [20]. This underlines that
knowledge of subsite cooperativity effects can be medically very
important. Subsite cooperativity is difficult to study experimentally
but probably exists in many enzymes. A review on subsite
cooperative effects in proteases, that summarizes the available
information concerning this interesting phenomena, has recently
Table 4. Potential novel thrombin substrates.
ID/Functional
grouping Name (Presumable) function Motif Positions
Location in
protein
Protein
expression
P12110
A BCD
Collagen a2(VI) chain Cell-binding protein PRGPR 568–572 Secreted Fibroblasts, placenta,
uterus
P113942
A BCD
Collagen a2(XI) chain Trimer a1(XI), a2(XI), a3(XI) may
control growth of collagen II fibrils
PRSAR
PRGQR
176–180
845–849
Secreted Cartilage
P12111
A BCD
Collagen a3(VI) chain Cell-binding protein PRGNR 2366–2370 Secreted Fibroblasts, placenta,
plasma
Q14050
A BCD
Collagen a3(IX) chain Structural component of hyaline cartilage PRGLR 230–234 Secreted Skin, cartilage
Q9UQ03
A B C D
Coronin-2B Reorganization of neuronal actin structure PRAAR 397–401 Brain
Q14118
A BCD
Dystroglycan Cell-matrix interaction; laminin
receptor; target for M. leprae
PRTPR 453–57 Secreted;
30–653 a-dystroglycan
Skeletal muscle
P27539
A B C D
Embryonic growth/
differentiation factor 1
Embryonic tissue differentiation PRSLR 210–214 Secreted; 30–253
propeptide
Brain
P05305
ABC D
Endothelin-1 Vasoconstriction PRSKR 88–92 Secreted;
90 end of big
endothelin 1
Lung, placenta
Q06828
A BCD
Fibromodulin Rate of fibrils formation, binds to
collagen type I and II
PRSLR 175–179 Secreted;
168–188
LRR-5 2
P41439
ABCD
Folate receptor c Binds folate PRSAR 22–26 Secreted,
1–23 signal sequence
Spleen, thymus, bone
marrow; ovary and
uterine carcinoma
P09681
ABCD
Gastric inhibiory
polypeptide
Stimulates insulin release, inhibits
gastric acid secretion
PRGPR 47–51 Secreted;
22–50 propetide
O60391
A B CD
Glutamate (NMDA
receptor subunit 3B
Ion channel in prosynaptic
membrane
PRALR 469–473 23–564 ED Brain, motorneurons
Q9NZ20
ABCD
Group 3 secretory
phospholipase A2
Phospholipid metabolism PRAIR 444–448 Secreted Kidney, heart, liver,
skeletal muscle
Q96RW7
A BCD
Hemicentin-1 (Fibulin-6) Part of ECM PRGYR 5301–5305 5272–5307 EGF-
like 5; Ca
2+-binding
Fibroblasts, retinal
pigment epithelium
Q86UW8
ABC D
Hyaluron and proteo-
glycan link protein 4
Binds to hyaluronic acid,
formation of ECM
PRGGR 169–173 Secreted;
163–268 link 1
Brain
Q9UMF0
ABCD
ICAM-5 Binds to LFA-1 PRAPR 629–633 32–825 ED Brain
Q969P0
A B C D
Immunoglobulin
superfamily member 8
Cell motility and proliferation, NS
development, fertilization
PRSHR 524–528 28–579 ED; 431–560 Ig-
like C2 type 4
Brain, kidney, testis,
liver, placenta
Q13349
A B C D
Integrin aD (CD11d) Receptor for ICAM-3 and VCAM1,
lipoprotein clearance, antigen clearance
PRGQR 497–501 18–1100 ED Blood cells
P38570
A BCD
Integrin aE pre-cursor PRTKR 58–62 19–1124 ED Intraepithelial T cells
P20701
A BCD
Integrin aL (CD11a) aL/b2 is receptor for ICAM-1, -2, -3 and –4;
cytotoxicity
PRAGR 39–43 26–1090 ED Leukocytes
P06756
A B C D
Integrin aV
(CD51)
Receptor for vitronectin, fibronectin,
fibrinogen, prothrombin, laminin,
thrombospondin
PRAAR 274–278 31–992 ED
Hits holding the consensus P-R-[AGST]-[not DE]-R in an extra-cellular or secreted part are listed alphabetically by name. In the column to the left, A in bold and larger
font indicates (presumable) involvement in cell adhesion, B in the nervous system, C in the cardiovascular system, and D in development/differentiation. ED, extra-
cellular domain; 7-TM, seven-transmembrane receptor; PBL, peripheral blood leukocytes.
doi:10.1371/journal.pone.0031756.t004
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factor Xa by Bianchini et al from 2002 also comes to the
conclusion that the efficiency in cleavage by factor Xa is primarily
a result of exosite interactions and not the specificity of the active
site [40]. This article also contains a detailed study of the cleavage
specificity of human thrombin. In this article thrombin was used as
a reference compound for the analysis of Factor Xa. By using a
large panel of fluorescence-quenched substrates they mapped the
cleavage specificity of thrombin between P3 and P39residues [40].
Their results are very similar to results we obtain for this region by
phage display. For example, they did see that the P3 position is
relatively unspecific with a slight preference for methionine,
threonine and arginine. In the P2 position they see that proline is
Table 5. Potential novel thrombin substrates.
ID/Functional
grouping Name (Presumable) function Motif Positions Location in protein Protein expression
P20702
A B C D
Integrin aX (CD11c) Receptor for fibrinogen PRGWR 498–502 20–1107 ED Monocytes,
granulocytes
P16144
A BCD
Integrin b4 precursor
(CD104)
a6/b4 is receptor for laminin PRGLR 378–382 28–710 ED Epithelia
Q9Y6N6
A BCD
Laminin subunit c3 Organization of embryonic
cells into tissues
PRSGR 443–447 Secreted; 430–479
EGF-like 4
Skin, heart, repro-
ductive tracts, lung
O15230
A BCD
Laminin subunit a5 Organization of embryonic
cells into tissues
PRSSR 3372–3376 Secreted; 3340–3513
laminin-like 4
Heart, muscle, lung,
placenta, kidney,
retina, pancreas
O75610
ABCD
Left-right deter-
mination factor 1
Left-right axis determination PRSAR 138–142 Secreted; 132–135
R-X-X-R site
Colon, pancreas,
spleen
Q9NT99
ABCD
Leucin-rich repeat-
containing protein 4B
PRSSR 543–547 36–576 ED
Q9NZU1
ABCD
Leucin-rich repeat
transmembrane
protein FLRT1
Cell adhesion, receptor
signaling
PRSLR 98–102 21–524 ED
78–98 LRR2
99–121 LRR3
Kidney, brain
Q9NZR2
A B CD
Low-density lipoprotein
receptor-related protein
1B
Receptor-mediated
endocytosis
PRSAR 2605–2609 ED 25–4444; 2590–2626
LDL receptor class A13
Thyroid and salivary
gland; adult and fetal
brain
Q9NPA2
A BCD
Matrix
metalloproteinase-25
Activate progelatinase 1 PRAPR 515–519 Mature form 108–539 Leukocytes, lung,
spleen
P58417
A B CD
Neurexophilin-1 Resembles neuropeptides PRAKR 102–106 Secreted; 98–176.
region III
Brain
Q9UM47
ABCD
Neurogenic locus
notch homolog
protein 3 (Notch 3)
Regulates cell-fate
determination
PRGFR
PRGPR
PRARR
109–113
1308–1312
1567–1571
ED 40–1643 78–118
EGF-like 2
1289–1325 EGF-like 33
ubiquitous
Q99466
ABCD
Neurogenic locus
notch homolog
protein 4 (Notch 4)
Regulates cell-fate
determination. branching
in the vascular system
PRGRR 1911–1915 1432–2003 extra-
cellular. truncation
Heart, lung, placenta
Q8N729
A B C D
Neuropeptide W Regulates neuroendocrine signaling,
stimulates water and food intake
PRSPR 115–119 Secreted Substantia nigra, fetal
kidney and trachea
Q14112
A BCD
Nidogen-2 Cell-ECM interactions; binds to
collagens I and IV, perlecan, laminin 1
PRSAR 145–49 Secreted;
198–273 NIDO domain
Heart, placenta, bone
Q8NG85
A B CD
Olfactory receptor 2L3 Putative odorant receptor PRSLR 261–265 259–271 ED
Q8NG80
A B CD
Olfactory receptor 2L5 Putative odorant receptor PRSLR 261–265 259–271 ED
Q8NGY9 Olfactory receptor 2L8 Putative odorant receptor PRSLR 261–265 259–271 ED
A B CD
O60542
A B C D
Persephin Neurotropic activity, development
of the CNS
PRGAR 98–102 Secreted
Q8TCZ9
ABCD
Polycystic kidney and
hepatic disease 1
Differentiation of bile collecting
duct, biliary differentiation
PRGGR 3236–3240 24–3858 ED Kidney, liver, pancreas
Q9P2E7
ABCD
Protocadherin-10 Ca
2+-dependent cell adhesion PRTGR 395–399 19–715 ED; 251–358
cadherin 3
Brain. testis, ovary
Q9H158
ABCD
Protocadherin
alpha C1
Ca
2+-dependent cell adhesion; specific
neuronal connections in the brain
PRSAR 571–575 19–683 ED; 570–667
cadherin 6
Brain
O95206
ABCD
Protocadherin-8 Ca
2+-dependent cell adhesion PRSGR 301–305 30–749 ED; 247–354
cadherin 3
Brain
Hits holding the consensus P-R-[AGST]-[not DE]-R in an extra-cellular or secreted part are listed alphabetically by name. In the column to the left, A in bold and larger
font indicates (presumable) involvement in cell adhesion, B in the nervous system, C in the cardiovascular system, and D in development/differentiation. ED, extra-
cellular domain; 7-TM, seven-transmembrane receptor; PBL, peripheral blood leukocytes.
doi:10.1371/journal.pone.0031756.t005
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activity of this substrate than with leucine or valine in this position.
In the P19position they identify serine, alanine, glycine and
threonine as the four most preferred aa. This is in full agreement
with our data and with data from several other labs. However, in
contrast to our results they find that phenylalanine is also well
tolerated in this position [40]. In the P29position they observe a
preference for aromatic aa, which is in agreement with our results.
The strong preference for arginine in the P39position is also
identical between the two studies [40].
Interestingly none of the in vivo substrates identified (listed in
Figure 1) have both the P2 proline and the P39arginine of the
consensus site. This may indicate that suboptimal cleavage sites
are preferred over the consensus site. The sequences of the in vivo
substrates show a cleavage that is 10–100 times less efficient than
the consensus site. The analysis of four selected ‘‘in vivo’’ sites also
substantiate this conclusion by showing that these four sites were
only cleaved at an efficacy of 1–30% of the consensus site (Fig. 4C
and 4D). This is a finding that may seem puzzling. However, a too
efficient cleavage may potentially cause excessive coagulation and
a risk of unwanted thrombosis. A similar situation has been
observed in the skin where the serine proteases kallikrein 5 and 7
are present in a region where the pH is suboptimal for maximal
cleavage [41]. Both of these enzymes have a slightly basic pH
optimum, whereas the outer layer of the skin has an acidic pH. By
artificially increasing the pH, as for example by the use of neutral
or alkaline soaps, the serine protease activity increases [42]. This
increase in protease activity leads to premature degradation of
corneodesmosomes, inactivation of b-glucocerebroside and acidic
sphingomyelinase and subsequent impairment of epidermal
barrier function [41,42]. Here the protease activity has to
apparently be kept under suboptimal conditions as to not cause
tissue damage.
A second and more likely explanation is that long distance
subsite cooperative effects play a major role in determining the
specificity [43,44]. It is well known that the specificity of the
interaction between thrombin and its substrates stems not only
from the interaction of the substrate with the catalytic subsites
from S4 to S49, but also from interactions with the anion binding
exosites I and II, also called the fibrinogen-recognizing exosite and
the heparin-binding exosite, respectively. These two exosites are
positively charged domains that flank the active site. These sites
interact with negatively charged regions of the substrate. Such
interactions may thereby compensate for lack of direct strong
interactions with the active site. There is even indications that
exosite interactions may be the major source of substrate
Table 6. Potential novel thrombin substrates.
ID/Functional
grouping Name (Presumable) function Motif Positions Location in protein Protein expression
Q9Y6N7
A B C D
Roundabout homolog 1
(H-Robo-1)
Guides cellular migration, axon
development
PRSHR 115–19 26–897 ED;
68–164 Ig-like C2-type 1
Widely expressed (not in
kidney)
Q9HCK4
A B C D
Roundabout homolog 2
(ROBO2)
Guides cellular migration, axon
development
PRSHR 78–82 22–859 ED;
3 1 – 1 2 7I g - l i k eC 2t y p e1
Ovary, brain
Q96MS0
A B C D
Roundabout homolog 3
(ROBO3)
Guides cellular migration, axon
development, spinal chord
development
PRAHR 115–119 21–891 ED;
6 4 – 1 6 0I g - l i k eC 2t y p e1
P09683
ABCD
Secretin Stimulates secretion of NaHCO3 from
pancreas, inhibits release of gastric acid
PRARR 23–27 Secreted;
19–26 propeptde
O94933
A B C D
SLIT and NTRK-like
protein 3
Suppresses neurite outgrowth PRTPR 339–343 29–654 ED Cerebral cortex
O60721
A B CD
Sodium/potassium/
cal-cium exchanger 1
Sensory transduction, vision PRGRR 192–196 1–452 ED Retinal rod
Q99523
A B C D
Sortilin Clearance receptor on cell surface,
promotes neuronal apoptosis,
receptor for neurotensin, osteogenesis
PRGGR 70–74 34–77 propeptide Brain, spinal chord, heart,
thyroid, testis, placenta,
skeletal muscle
A2VEC9
ABC D
SCO-spondin Formation of the CNS, neuronal
aggregation
PRGWR 1579–1583 Secreted; 1564–1600
LDL-receptor class A5
P22105
A BCD
Tenascin X Cell-ECM interactions PRAVR 1500–1504 Secreted; 1459–1540
fibronectin type II7
Fetal adrenal, testis, muscle
O95407
A B C D
Tumor necrosis factor
receptor super family
member 6B
Inhibits apoptosis PRAGR 246–250 Secreted Fetal brain, lung, liver, adult
tissues
Q8WY21
A B C D
VPS10 domain-containing
receptor SorCS1
Neuropeptide receptor PRTPR 797–801 ED 34–1099 Fetal/infant brain, fetal
retina
Q96PQ0
A B CD
VPS10 domain-containing
receptor SorCS2
Neuropeptide receptor PRGVR 419–423 ED 51–1878 Brain, kidney
Q9Y493
A BCD
Zonadhesin Binding of sperm to egg PRGLR 2622–2626 ED 18–2757 Sperms
Q9BS86
A BCD
Zona pellucida-binding
protein 1
Gamete interaction PRAFR 50–54 Secreted (45–351) Testis
Hits holding the consensus P-R-[AGST]-[not DE]-R in an extra-cellular or secreted part are listed alphabetically by name. In the column to the left, A in bold and larger
font indicates (presumable) involvement in cell adhesion, B in the nervous system, C in the cardiovascular system, and D in development/differentiation. ED, extra-
cellular domain; 7-TM, seven-transmembrane receptor; PBL, peripheral blood leukocytes.
doi:10.1371/journal.pone.0031756.t006
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thrombin does, for example, increase by approximately 1500 fold
by interaction with thrombomodulin and by approximately
10 000 fold by interaction with thrombomodulin in the presence
of phospholoipid membranes [43]. The mechanisms of this
cooperative effect is not fully known but it is unlikely that the
exosite interaction has any dramatic effect on the specificity of the
active site of thrombin. Instead, the effect of the exosite is probably
primarily in recruiting the substrates. A potent such recruitment
effect may result in an increase in the local concentration of the
substrate and a more efficient cleavage.
The list of potential natural substrates for thrombin in Figure 1
is by no means a complete list. Many other potential in vivo sites
have been identified. For example, three sites identified in the
thrombin sensitive region of protein S (R49, R60 and R70) also
have sequences that indicate that they are far from optimal sites for
thrombin (VCLRSFGT, TAARQSTN, PDLRSCVN) [45], One
important cleavage site for thrombin in thrombin-activable
fibrinolysis inhibitor (TAFI) is arginine 302 [46]. This site
(SYTRSKSK) also markedly differs from the consensus site. It
thereby appears as if the absolute majority of the identified in vivo
sites for thrombin are relatively poor sites for this enzyme and that
other interactions probably play a major role in determining the
efficiency in cleavage.
The availability of the substrate site also probably has a major
impact on the efficiency of cleavage. If the site is exposed, in an
accessible surface loop, it may be efficiently cleaved. However, if
the site is located in a region where thrombin has difficulties in
contacting the site, the cleavage may be very inefficient
irrespective if the consensus sequence is present. The recombinant
substrates used in this analysis have the cleavable sequences in an
accessible conformation, which enables an unbiased comparison of
the cleavage specificity, whereas the natural substrates may vary
considerable in accessibility. This has to be taken into consider-
ation when comparing the efficiency in cleavage of the different
natural substrates. However, the consensus cleavage site for
thrombin is relatively heavily charged with two arginines as well as
having a proline, which introduces a bend in the peptide chain
indicating that most consensus sites are probably exposed on the
surface of the potential target molecules.
The phage display analysis also resulted in several additional
findings concerning important restrictions in aa tolerated in
various positions of the cleavage site for human thrombin. For
example, the complete lack of aromatic aa in the P19position of the
substrates was very interesting. The aa in this position seems to be
of major importance as very little variation is observed among all
identified in vivo substrates and no aa other than glycine/alanine/
serine and threonine was seen among the substrates obtained in
the phage display analysis (Fig. 1). The only in vivo sites for
thrombin that avoid this pattern are protein C and coagulation
factor XI, which in this position have a leucine or an isoleucine,
respectively (Fig. 1). Introduction of a tryptophan in this position
of the consensus sequence resulted in a complete block in cleavage,
which shows the importance of this position in substrate selection.
Introducing an aspartic acid in this position also completely block
cleavage whereas a leucine resulted in a reduction in cleavage rate
by a factor 10 (Fig. 4C). Large aromatic aa are apparently not
tolerated, possibly except phenylalanine [40], and negatively
charged aa also severely effect cleavage in this position. However,
aromatic aa are tolerated, and even potentially favored, in other
positions, such as in the P29 position (Figs. 1 and 4C).
Among the sequences originating from the phage display
analysis we see an almost complete lack of negatively charged aa in
all eight positions from P4 to P49 (Fig. 1). Introduction of an
aspartic acid into position P2 and P19 resulted in complete block in
cleavage and in the P29position aspartic acid resulted in a drop in
cleavage rate by approximately 15 times. Interestingly, the
introduction of this negatively charged aa in the P4 position,
which is relatively far from the actual cleavage site, resulted also in
a dramatic drop in cleavage rate by a factor 20–30 (Fig. 4A). These
findings indicates that introduction of a negatively charged aa in
almost any position, maybe except the P49 and the P3 positions,
are accompanied with severe effects on the cleavage rate. The
marked negative effect of introduction of an aspartic acid in the P4
position of substrates also shows that positions relatively far from
the cleavage site can be of major importance for efficient cleavage.
The kinetic parameters of an enzyme that has been established
using short synthetic substrates, where the substrates normally are
only three or four aa long and either lack all aa N or C terminal of
the cleavage site should be considered only qualitatively. Such
kinetic parameters have probably little relevance to the actual in
vivo situation with natural protein substrates.
The complete lack of cleavage of the P19 tryptophan mutant
and the two mast cell chymase sites, even after prolonged cleavage,
also shows the very high specificity displayed by human thrombin.
This is in marked contrast to many other serine proteases, for
example the mast cell chymases, which after prolonged cleavage
shows activity towards a relatively broad range of substrates
[29,30,47].
A relatively detailed picture of all the eight positions that may
contribute to the substrate specificity of human thrombin has now
been obtained by the phage display analysis in combination with
the recombinant substrates. These results may also promote the
identification of novel substrates, for example by contributing
consensus motifs and individual cleavage-susceptible sequences
for database searches. Our ProSite search with the refined
consensus P-R-[AGST]-[not DE]-R has lead to the identification
of 73 potential novel targets (Tables 3, 4, 5, and 6). These group
in the fields of cell adhesion, the nervous system, development/
differentiation and circulatory homeostasis. However, when
evaluating these new potential substrates we need to keep in
mind the possibility that numerous potential targets may be
missed, due to that most of the in vivo sites that so far have been
identified are not consensus sites. However, a very broad
screening gives too many potential sites to be able to handle in
this type of analysis.
Thrombin has previously been shown to digest numerous ECM
components, such as nidogen, fibronectin, laminin and type V
collagen [48,49,50]. The potential novel substrate integrin aVi s
therefore especially interesting, because it is a receptor for several
previously known thrombin substrates, including prothrombin,
fibronectin and laminin. The digestion of these central ECM
molecules by thrombin may have important medical implications,
for example in preventing the metastatic crossing of the ECM by
tumors, and in wound healing.
The idea that thrombin may play an important role in the
development and function of the brain has previously been
indicated from the fact that the protease is expressed in various
brain regions, especially during development and in regions
exhibiting plasticity [51]. Thrombin has also been implicated in
pathologic brain conditions, including adverse processes following
CNS injury [52,53,54,55,56], and may influence the direction of
neurite outgrowth [57]. Indeed, several novel candidate substrates
have neurotropic functions, such as Roundabout homologs 1, -2
and –3 and persephin. Although the described target for many
processes in the nervous system by thrombin is PAR-1
[5,53,56,58,59,60], alternative targets may very well exist.
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combination with the newly developed recombinant substrates has
made it possible to determine the substrate recognition profile of
the active site of thrombin, from position P4 to P49, completely
and simultaneously. This study has also resulted in a very detailed
picture concerning kinetics, in relative terms, on the contribution
by individual residues on cleavage specificity. The combination of
these two techniques has made it possible to study the specificity of
the catalytic site excluding interactions depending on exosite
interactions. The obtained profile conforms very well with
previous studies, and adds important kinetic parameters to these
results with substrates having not only aa either N or C terminal of
the cleavage site but the entire eight aa acids of the extended
specificity. One very interesting finding is that most natural
substrates are not optimal substrates for thrombin, which indicates
that cleavage of such sites in the absence of strong exosite
interactions, may lead to a too efficient cleavage, and this may
cause excessive coagulation and a risk of unwanted thrombosis.
Exosite interactions may here facilitate the interaction between
enzyme and substrate and increase the kinetics and also substrate
specificity in cleavage. In addition, the use of the consensus site to
screen the human proteome has resulted in the identification of a
panel of 73 potentially novel substrates for thrombin, some of
them may prove to be important targets for this multi-facetted
enzyme.
Materials and Methods
Thrombin
Lyophilized powder of human plasma thrombin (SIGMA T-
6884) was diluted in double-distilled water to a concentration of
0.2 NIH units/ml. One U or 0.2 U of diluted thrombin were used
in two separate phage display analyses.
Analysis of thrombin’s extended recognition sequence
by substrate phage display
The cleavage specificity of thrombin was investigated with a T7
phage-displayed peptide library containing approximately 5610
7
individual nonamers as previously described [21,28,33,47]. In this
library, randomized nonamers are inserted in the carboxy-terminus
of T7 capsid protein 10A, followed by a six-histidine tag (His6-tag)
for purification. The constant region at the amino-terminal flank of
the peptides consists of the aa proline-glycine-glycine, breaking any
secondary structures imposed by the capsid protein. In brief, phages
are anchored to nickel nitrilotriacetic acid (Ni-NTA) beads via the
His6-tags before the first protease treatment. The protease is added
and allowed to react over night, releasing phages displaying
cleavage-susceptible 9-mers from the beads. Samples are centri-
fuged and cleaved phages are collected in the supernatant. These
phages are amplified in the E. coli strain BLT5615 and enter the
next selection round (biopanning). After five biopannings, enriched
cleavage-susceptible phages are sequenced.
For the analysis of thrombin, an aliquot of approximately 10
9
plaque-forming units was immobilized on 100 ml Ni-NTA agarose
beads and incubated 1 hr with gentle rotation at 4uC. Unbound
phages were removed by ten washes with 1.5 ml 1 M NaCl, 0.1%
Tween-20 in PBS, pH7.2, and two subsequent washes with 1.5 ml
PBS. The beads were resuspended in 1 ml PBS. One U or 0.2 U
of thrombin were added and control samples with PBS instead of
protease were run in parallel. Zero point two U/ml corresponds to
a thrombin concentration of approximately 1.5 nM. Note the
137 mM sodium concentration in PBS implies that most of the
thrombin is expected to be in the ‘‘fast’’ form [61]. Digestion and
mock-digestion proceeded over night at room temperature under
gentle rotation. Samples were centrifuged briefly on a tabletop
centrifuge, pelleting the Ni-NTA beads. A control elution of the
phages remaining bound to the Ni-NTA beads, using 100 ml
100 mM imidazole, concluded that at least 1610
8 phages were
attached to the matrix in each selection round. Cleavage-
susceptible phages were recovered, amplified and selected in five
rounds as described earlier [21,28,33].
Fifty plaques were then arbitrarily isolated from Luria broth
(LB) ampicillin (amp) plates representing biopannings with 1 U
and 0.2 U of thrombin. Each plaque was dissolved in 100 ml phage
extraction buffer (100 mM NaCl and 6 mM MgSO4 in 20 mM
Tris-HCl, pH 8.0) and shaken vigorously for 30 min. Phage DNA
from the variable region in the capsid 10A gene was amplified by
PCR with vector-specific primers. PCR fragments were purified
with the Omega-BioTech’s E.Z.N.A
TM micro elute kit (Omega
Biotech, Vancouver Island, Canada). Purified PCR fragments
were sequenced on an ABI PRISMH 3700 DNA Analyzer.
Nineteen and 18 individual inserts coding for cleavage-susceptible
peptides were sequenced from plaques representing selection with
1 U or 0.2 U of thrombin, respectively. One sequence containing
a stop mutation (from selection with 1 U thrombin) and one
sequence file of bad quality (from selection with 0.2 U of
thrombin) were discarded.
Alignment of sequenced phage inserts
Phage insert sequences were aligned with the program
Consense (Anders Kaplan and Maike Gallwitz, unpublished).
Settings were chosen to retrieve patterns of at least four aa.
Approximately functional equivalent aa were grouped as follows:
aromatic aa (phenylalanine, tyrosine, tryptophan); negatively
charged aa (aspartate, glutamate), positively charged aa (arginine,
lysine, histidine), small aliphatic aa (glycine, alanine), larger
aliphatic aa (valine, leucine, isoleucine), others (proline, serine,
threonine, cysteine, methionine, glutamine, asparagine).
Generation of recombinant substrates for the analysis of
the cleavage specificity
A new type of substrate was developed to verify the results
obtained from the phage display analysis. Two copies of the E. coli
thioredoxin gene were inserted in tandem into the pET21 vector
for bacterial expression (Fig. 3A). In the C-terminal end, a His6-
tag was inserted for purification on Ni-NTA agarose beads
(Qiagen, GmbH, Hilden, Germany). In the linker region, between
the two thioredoxin molecules, the different substrate sequences
were inserted by ligating double stranded oligonucleotides into two
unique restriction sites, one BamHI and one SalI site (Fig. 3A). The
sequences of the individual clones were verified after cloning by
sequencing of both DNA strains. The plasmids were then
transformed into the E.coli Rosetta gami strain for protein
expression (Novagen, Merck, Darmstadt, Germany). A 10 ml
overnight culture of the bacteria harbouring the plasmid was
diluted 10 times in LB Amp and grown at 37uC for 1–2 hr until
the OD600 reached 0.5. Isopropyl b-D-1-thiogalactopyranoside
(IPTG) was then added to a final concentration of 1 mM. The
culture was grown at 37uC for an additional 3 hr under vigorous
shaking, after which the bacteria were pelleted by centrifugation at
3500 rpm for 12 min. The pellet was washed once with 25 ml
PBS and 0.05% Tween 20. The pellet was then dissolved in 2 ml
PBS and sonicated 6630 seconds to open the cells. The lysate was
centrifuged at 13000 rpm for 10 min and the supernatant was
transferred to a new tube. Five hundred ml of Ni-NTA slurry
(50:50) (Qiagen, Hilden, Germany) was added and the sample was
allowed to slowly rotate for 45 min at RT. The sample was
transferred to a 2 ml column allowing the supernatant to slowly
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protein in the column. The column was washed four times with
1 ml of washing buffer (PBS, 0.05% Tween, 10 mM Imidazole,
1 M NaCl). Elution of the protein was achieved by adding 150 ml
elution buffer (PBS, 0.05% Tween 20, 100 mM Imidazole)
followed by five 300 ml fractions of the elution buffer. Each
fraction was collected individually. Ten ml from each of the eluted
fractions was mixed with 1 volume of 26sample buffer and 1 ml b-
mercapto-ethanol and subsequently heated for 3 min at 80uC.
The samples were analyzed on 4–12% pre cast SDS bis-tris PAGE
gels (Invitrogen, Carlsbad, CA, USA) and the fractions that
contained the most protein were pooled. The protein concentra-
tion of the combined fractions was determined using the Bio-Rad
DC Protein assay (Bio-Rad Laboratories Hercules, CA USA).
Approximately 60 mg of recombinant protein was added to each
120 ml cleavage reaction (in PBS). Twenty ml from this tube were
removed before adding the enzyme, the 0 minute time point. The
active enzyme was then added and the reaction was kept at room
temperature during the entire experiment. Twenty ml samples
were removed at the indicated time points (15 min, 30 min,
45 min, 60 min and 150 min) and the reactions were stopped with
the addition of one volume of 26 sample buffer. One ml b-
mercapto-ethanol was then added to each sample followed by
heating for 3 min at 80uC. Twenty ml from each of these samples
was analyzed on 4–12% pre-cast SDS bis tris PAGE gels
(Invitrogen, Carlsbad, CA, USA). The gels were stained over
night in colloidal Coomassie staining solution and de-stained for
several hours according to previously described procedures [62].
The intensity of the individual bands on the gel was determined
from scanned high-resolution pictures by densitometric scanning
of the gels and the program ImageJ (rsb.info.nih.gov/nih-image/).
In order to obtain good estimates of the differences in activity
towards different substrates different concentrations of the enzyme
were used in several individual experiments. The combined results
from these different gels were then used to get an accurate estimate
of the difference in activity against the various substrates.
PROSITE scan for the Phage Display consensus motif
The Swiss-Prot, TrEMBL and PDB databases were searched by
a PROSITE Pattern Scan (http://www.expasy.ch/tools/scanpro-
site/) for human (Homo sapiens) proteins holding the consensus
motif derived from sequenced phage inserts, P-R-[AGST]-[not
DE]-R. No description filter was chosen, at most one character
was allowed to match a conserved position in the pattern, and the
match mode was set to ‘‘greedy, overlap, no includes’’. Protein hits
were assessed individually for the localization of the motif,
expression pattern and presumable function. A number of
hypothetical or poorly characterized proteins were not further
assessed.
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